PCM
PSTX

Prelude Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Prelude Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,250
Closed -$50K – 2121
2022
Q1 		$50K Buy
+11,250
New +$50.7K ﹤0.01% 1488

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's PSTX Position: Q2 2022 in Review

Prelude Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2022, closing a stake of 11,250 shares — an estimated $50K sold.

Prelude Capital Management first reported a position in PSTX in Q1 2022 and held it in 1 quarter. The position peaked at $50K in Q1 2022. 56 funds tracked by Wall St. Rank hold PSTX as of Q2 2022.

  • Prelude Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Prelude Capital Management sold 11,250 Poseida Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $50K.
  • Prelude Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Prelude Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $50K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Prelude Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.